Hot Mandates: Texas-based Family Office

8 Mar

A Dallas, Texas based VC firm that was founded in 2011 and is focused on healthcare companies. The firm makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to investing in syndicates. The firm primarily invests in companies that are based in Texas but is open to opportunities across North America. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, digital health, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Hot Mandates: Australia-Based Impact Investor

8 Mar

A newly founded investment firm based in Melbourne, Australia. The firm manages an open-ended, evergreen fund that focuses on life science investments. The firm invests in both early-stage and late-stage companies with a slight focus on the latter. In early-stage companies, the size of initial investment is between $1-5M. The firm is a provider of continuous capital and will continue to support portfolio companies through follow-on investments (provided milestones are met). The firm is open to global investments and does not require an Australia angle.

The firm invests broadly across the life sciences, including therapeutics, medical devices, diagnostics, digital health, and ag-bio, with 4 key investment themes that they closely navigate. The 4 themes are (1) personalized/precision medicine (i.e. NGS, big data), (2) infectious diseases and drug resistance (i.e. vaccines, anti-bacterials, rapid diagnostics), (3) “healthspan” (i.e. preventative and regenerative medicine, wellness, anything that slows the aging process, chronic diseases and age-related diseases), and (4) feeding the world (i.e. sustainable proteins, biological solutions for farmers, water and air purification technologies). The firm is stage agnostic and will consider technologies that are as early as pre-PoC.

The firm seeks to work with companies with innovative, highly disruptive technologies in the biotech/medical space. The firm is an active investor, meaning that the firm will work closely with portfolio companies to support their growth post-initial investment. The firm’s team has a broad range of experience in life sciences investments, funds management, international business development, etc., through which the firm provides strategic support. The firm prefers to lead and seek board representation, but this is not always the case.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Got a Moment for a Great Match?

4 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireHealthtech Partnering Week (HPW) launches in just over a week, and the team at Life Science Nation (LSN) is proud to welcome 400+ investors to our digital platform to source portfolio assets across life science and healthcare. LSN works with exceptional early-stage companies to connect them with investors and strategic partners that are a fit for their product and stage of development, and one of the most powerful ways that is done is through digital partnering events where attendees can filter through hundreds of opportunities and find the best fits for their needs.

Check out our current list of confirmed investors and sign up to begin booking meetings and making deals!

Confirmed Digital RESI March Investors and Strategic Partners

Confirmed RESI Investors Confirmed 4D Meets AI Investors Confirmed LHI Investors

It Takes a Village

4 Mar

By Rory McCann, Marketing Manager & Conference Producer, LSN

Life Science Nation (LSN)’s 4D Meets AI is taking a closer look at strategic partnerships March 18-19. The question kept coming up over the past several months, particularly with companies working with AI: What should early-stage fundraising companies be looking for beyond a check? Should they be prioritizing technology or team fit, market strategy, industry expertise, service provider connections, etc.? To answer these questions, we are bringing the buyers and sellers together to discuss these topics and more.

Each 4D Meets AI panel features investors in AI technology and their portfolio companies to discuss their process, from pitch to partners, in order that current fundraising executives can broaden their definition of what a successful partnership looks like and use it to inform their process. Additionally, Renee Yao, Global Healthcare AI Startups Lead at NVIDIA joins the program to showcase outstanding startups in the Inception accelerator, highlighting yet another style of partnership designed to support AI companies.

Early-stage entrepreneurship can be a challenging journey that truly takes a village of community support. 4D Meets AI is broadening the definition of what successful partnering looks like in order that fundraising executives can take advantage of the many relationships necessary for growth. We hope you’ll join us and lend your voice to the conversation!

McDermott Will & Emery joins HPW as Title Sponsor

4 Mar

By Gregory Mannix, Vice President International Business Development, LSN

Life Science Nation (LSN) is joining forces with McDermott Will & Emery to bring insight and education to the community of investors, service providers, and early-stage companies at Healthtech Partnering Week (HPW). HPW features McDermott Will & Emery at Redefining Early Stage Investments (RESI), March 15-17 and 4D Meets AI, March 18-19.

At RESI, the MWE team will showcase their insights and expertise working with successful organizations to achieve their goals for over eighty-five years. The firm will host a workshop on the all-important topic of Negotiating Term Sheets. This interactive workshop will provide wisdom to early stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion.

Partner Brian Malkin, JD will also moderate 4D Meets AI’s Drugs panel discussing the importance of early-stage partnerships in therapeutics and highlighting investors speaking with their portfolio companies on the secrets to their successful partnerships

Sign up for HPW to get to know the MWE team and learn how their team is partnering with entrepreneurs to move their companies forward. Attendees for both RESI and 4D Meets AI can save on bundle pricing – Click here to learn more!

Get involved with sponsorship at Healthtech Partnering Week

Hot Investor Mandate: Global Firm’s Strategic Investment/Partnering Arm Interested in IVD and AI Technologies Across All Indications

4 Mar

A global firm with offices worldwide invests in medical technology companies that are strategically relevant to its parent company. The firm invests in new technologies via venture investing, collaborations, incubation, or M&A. The firm invests worldwide.

The firm’s primary focuses within healthcare include in-vitro diagnostics (particularly immuno and molecular diagnostics), digital lab services (including capacity management, care coordination, technologies that help physicians make diagnoses and other key decisions) and AI technologies in healthcare. The firm will invest in any medical indication area, and prefers companies that have at least attained proof of concept data or with a product on market demonstrating traction and revenue.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia Cross-Border VC Firm Invests in Therapeutics Companies Across the Globe, Open to All Modalities

4 Mar

A cross-border venture capital firm with offices in USA and Asia is investing from a fund with its major LPs being large Asian pharmaceuticals. Typically the firm makes an initial investment ranging from under $1 million to $3-6 million dependent on the company’s stage of development. The firm can allocate up to $16 million over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide, with a focus on opportunities in North America.

The firm only invests in therapeutics, and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry. The firm only invests in companies with technology that has the potential to be first in class.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →